Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

Completed · Not applicable · Has a placebo group

Conditions studied: Depression, Palliative Care, Cancer, Mental Disorder

In brief

The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.

Key facts

Study ID
NCT00129467
Run by
US Department of Veterans Affairs
People needed
47
Starts
2005-02-01
Expected to finish
2010-12-01
Last updated by the study team
2015-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.